Aiosyn, a company that develops AI-powered pathology algorithms for clinical diagnostics and life sciences, was awarded early-phase funding of Eur 250.000 by NWO (Dutch Research Council). This additional funding allows Aiosyn to accelerate its mission: increasing the adoption of artificial intelligence in pathology diagnostics and improving the chances of cancer patients worldwide.
Related news items
Aiosyn has been selected for Techleap's Pole Position Program28 October 2021
This program focuses on helping 10 ambitious companies within the medical field to reach the scaleup growth phase.read more